Resumen

Introduction: CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metabolic activity. Methods: We analyzed genetic variations in the promoter sequence of CYP2D6 gene for 71 hepatitis C negative and 15 hepatitis C positive subjects. Results: We found two novel genetic variants -1822AG; -1740CT, only in two patients with hepatitis C. Also, two linked new promoter sequence variations at –2060 GA and –2053 TG nucleotide positions that present in both hepatitis C negative and positive subjects are identified. The -2060 and -2053 variations are confirmed to be in linkage disequilibrium. The individuals with -2060A/A, and -2053G/G variation appeared to be associated with significantly lower levels of liver CYP2D6 mRNA. Analysis of CYP2D6 enzymatic activity in *1/*1 (wild type) subjects revealed that hepatitis C positive subjects expressed about 2.6-fold lower activity (24.0 ± 1.5 vs. 62.6 ± 3.7 pmol/min/mg; p = 0.0061) relative to hepatitis C negative. Conclusion: These data suggest that promoter variations -1822AG and -1740CT are present only in hepatitis C infected subjects. Hepatitis C positive individuals were associated with a lower liver CYP2D6 enzyme activity.

Palabras clave: CYP450 enzyme genotype phenotype genetic variant hepatitis.

2011-06-13   |   621 visitas   |   Evalua este artículo 0 valoraciones

Vol. 10 Núm.3. Julio-Septiembre 2011 Pags. 327-332 Ann Hepatol 2011; 10(3)